Background

After surgical correction of Tetralogy of Fallot (TOF), residual pulmonary regurgitation (PR), right ventricular (RV) dilatation and RV failure have been associated with adverse clinical events and are considered criteria for pulmonary valve replacement. Cardiovascular magnetic resonance imaging (CMR) is the gold-standard for eva-luation of these parameters. However it is an expensive technique which is not readily available in all hospitals and outpatient clinics. NT-proBNP is a biomarker which may overcome these CMR limitations and might be used as a cost-effective biomarker for monitoring patients with TF. The aim of this study is to evaluate whether NT-proBNP plasma levels may help as a biomarker for mon-itoring ventricular dilatation, pulmonary valve regurgita-tion and heart failure in patients with repaired TF Methods Single-centre observational prospective study including 40 patients (14.3±6.7 years, mean±standard deviation) with corrected TOF referred to our MRI unit. Data col-lection included: Clinical Parameters (electrocardiogram, chest X-ray, NYHA scale, time since last surgery)